abiraterone oral (SOL-804) / Bukwang Pharma, Solural Pharma - LARVOL DELTA

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SOL-804 in Healthy Male Subjects (clinicaltrials.gov) - P1 | N=48 | Completed | Sponsor: Bukwang Pharmaceutical | Recruiting ➔ Completed

Trial completion • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SOL-804 in Healthy Male Subjects (clinicaltrials.gov) - P1 | N=48 | Recruiting | Sponsor: Bukwang Pharmaceutical

New P1 trial • Genito-urinary Cancer • Oncology • Prostate Cancer

Bukwang Pharm aims for 3.9 trillion won market with prostate cancer treatment 'SOL-804' [Google translation] (eDaily) - "Bukwang Pharm (003000) has received permission to initiate phase 1 clinical trials for a new treatment for prostate cancer being developed through its subsidiary. It plans to apply for product approval next year....According to the Ministry of Food and Drug Safety on the 22nd, Dyna Therapeutics' new improved drug 'SOL-804' for prostate cancer treatment received phase 1 clinical trial plan (IND) approval on the 16th."

New P1 trial • Genito-urinary Cancer • Oncology • Prostate Cancer

Bukwang’s subsidiary wins patent for prostate cancer drug in 32 countries (Korea Biomedical Review) - "Bukwang Pharmaceutical its subsidiary Dyna Therapeutics obtained a composition patent for SOL-804, a prostate cancer drug candidate, in Korea and Japan....With the additional two patent registrations, Dyna has completed the patent registration in 32 countries including the U.S., Australia, Mexico, and Singapore....The company aims to apply for an additional clinical trial this year."

Patent • Genito-urinary Cancer • Oncology • Prostate Cancer